综述:慢加急性肝衰竭的新兴与当前管理
本文为叙述性综述,检索PubMed和Cochrane数据库截至2023年7月的文献,总结慢加急性肝衰竭(ACLF)的诊断标准、预后、流行病学和管理原则,并详细探讨静脉白蛋白、体外肝辅助装置、粒细胞集落刺激因子和肝移植四种干预措施。约35%的失代偿肝硬化住院患者患有ACLF,除肝移植外尚无公认的循证治疗。
要点
- 约35%的失代偿肝硬化住院患者患有ACLF。
- 欧洲肝病学会标准在前瞻性队列中建立,是国际上验证最充分的标准。
- 除肝移植外,ACLF尚无公认的循证治疗,多种方法在研究中。
核心结论
- ACLF被认识为不同于急性失代偿肝硬化的独立疾病实体,有助于临床更好地进行患者分层,促进更早与重症监护和肝移植团队协作。
- 未来十年的研究重点应聚焦探索新的治疗策略,尤其关注哪些ACLF患者应治疗、何时治疗以及如何治疗。
研究设计与样本
- 叙述性综述,检索PubMed和Cochrane数据库截至2023年7月发表的文章。
主要发现
- 约35%的失代偿肝硬化住院患者患有ACLF。
- 诊断ACLF的标准存在显著异质性,不同定义识别出不同表型且死亡率各异。
- 欧洲肝病学会制定的标准在前瞻性患者队列中建立,是迄今为止国际上验证最充分的标准。
- 在重症监护病房管理ACLF时,全身血流动力学不稳定、肾功能障碍、凝血功能障碍、神经功能障碍和呼吸衰竭是关键考虑因素。
关键数值与推荐
- 欧洲肝病学会标准在前瞻性患者队列中建立,是迄今为止国际上验证最充分的标准。
- 除肝移植外,ACLF尚无公认的循证治疗,但多种不同方法正在研究中。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute-on-chronic liver failure (ACLF) is a clinically and pathophysiologically distinct condition from acutely decompensated cirrhosis and is characterised by systemic inflammation, extrahepatic organ failure, and high short-term mortality. AIMS: To provide a narrative review of the diagnostic criteria, prognosis, epidemiology, and general management principles of ACLF. Four specific interventions that are explored in detail are intravenous albumin, extracorporeal liver assist devices, granulocyte-colony stimulating factor, and liver transplantation. METHODS: We searched PubMed and Cochrane databases for articles published up to July 2023. RESULTS: Approximately 35% of hospital inpatients with decompensated cirrhosis have ACLF. There is significant heterogeneity in the criteria used to diagnose ACLF; different definitions identify different phenotypes with varying mortality. Criteria established by the European Association for the Study of the Liver were developed in prospective patient cohorts and are, to-date, the most well validated internationally. Systemic haemodynamic instability, renal dysfunction, coagulopathy, neurological dysfunction, and respiratory failure are key considerations when managing ACLF in the intensive care unit. Apart from liver transplantation, there are no accepted evidence-based treatments for ACLF, but several different approaches are under investigation. CONCLUSION: The recognition of ACLF as a distinct entity from acutely decompensated cirrhosis has allowed for better patient stratification in clinical settings, facilitating earlier engagement with the intensive care unit and liver transplantation teams. Research priorities over the next decade should focus on exploring novel treatment strategies with a particular focus on which, when, and how patients with ACLF should be treated.
引用
- Butt MF, Jalan R. Review article: Emerging and current management of acute-on-chronic liver failure. Aliment Pharmacol Ther. 2023. PMID: 37589507. doi:10.1111/apt.17659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。